Search

Your search keyword '"Forconi, Francesco"' showing total 1,084 results

Search Constraints

Start Over You searched for: Author "Forconi, Francesco" Remove constraint Author: "Forconi, Francesco"
1,084 results on '"Forconi, Francesco"'

Search Results

1. Hairy cell leukemia variant and WHO classification correspondence Re: 5th edition WHO classification haematolymphoid tumors: lymphoid neoplasms

4. Activity of venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia: analysis of the VENICE-1 multicentre, open-label, single-arm, phase 3b trial

6. BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib

7. The efficacy and safety of venetoclax therapy in elderly patients with relapsed, refractory chronic lymphocytic leukaemia.

8. Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial

9. High surface IgM levels associate with shorter response to ibrutinib and BTK bypass in patients with CLL

11. Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia

12. KIR2DS2+ NK cells in cancer patients demonstrate high activation in response to tumour-targeting antibodies.

13. Mutations in the IgG B cell receptor associated with class-switched B cell lymphomas

15. Hairy cell leukemia and COVID-19 adaptation of treatment guidelines

16. Activity of venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia: analysis of the VENICE-1 multicentre, open-label, single-arm, phase 3b trial

18. Acalabrutinib monotherapy in patients with Waldenström macroglobulinemia: a single-arm, multicentre, phase 2 study

19. Proliferative History Is a Novel Driver of Clinical Outcome in Splenic Marginal Zone Lymphoma

20. Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease

22. Genome-wide association study identifies risk loci for progressive chronic lymphocytic leukemia

24. BCR signaling contributes to autophagy regulation in chronic lymphocytic leukemia

26. Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial

27. PB2331: AN ONGOING FIRST-IN-HUMAN PHASE 1 TRIAL OF NX-5948, AN ORAL BRUTON’S TYROSINE KINASE (BTK) DEGRADER, IN PATIENTS WITH RELAPSED/REFRACTORY B CELL MALIGNANCIES

28. S142: FOXO1-RICTOR AXIS INDUCES ADAPTIVE INCREASE IN AKT ACTIVITY DURING BCR INHIBITOR THERAPY IN CLL: IMPLICATIONS FOR COMBINATION THERAPY

29. PB2296: ROBUST BRUTON’S TYROSINE KINASE (BTK) DEGRADATION WITH NX-5948, AN ORAL BTK DEGRADER, IN A FIRST-IN-HUMAN PHASE 1A TRIAL IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY B CELL MALIGNANCIES

30. Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia

31. Development of DNA vaccines against B-cell neoplasms

32. Hairy cell leukemia variant and WHO classification correspondence Re: 5thedition WHO classification haematolymphoid tumors: lymphoid neoplasms

34. Supplementary methods and Figures from The Dual Syk/JAK Inhibitor Cerdulatinib Antagonizes B-cell Receptor and Microenvironmental Signaling in Chronic Lymphocytic Leukemia

35. Supplementary Figure 1 from Genetics and Prognostication in Splenic Marginal Zone Lymphoma: Revelations from Deep Sequencing

36. Supplementary Table 4 from Genetics and Prognostication in Splenic Marginal Zone Lymphoma: Revelations from Deep Sequencing

37. Supplementary Figure 2 from Genetics and Prognostication in Splenic Marginal Zone Lymphoma: Revelations from Deep Sequencing

38. Supplementary Tables 1-3 from Genetics and Prognostication in Splenic Marginal Zone Lymphoma: Revelations from Deep Sequencing

39. Supplementary Table 6 from Genetics and Prognostication in Splenic Marginal Zone Lymphoma: Revelations from Deep Sequencing

40. Supplementary Table 5 from Genetics and Prognostication in Splenic Marginal Zone Lymphoma: Revelations from Deep Sequencing

41. Supplementary Tables S1-S4 from The Prognostic Value of TP53 Mutations in Chronic Lymphocytic Leukemia Is Independent of Del17p13: Implications for Overall Survival and Chemorefractoriness

42. Supplementary Data from Stereotyped B-Cell Receptor Is an Independent Risk Factor of Chronic Lymphocytic Leukemia Transformation to Richter Syndrome

43. Data from STING Activation Reverses Lymphoma-Mediated Resistance to Antibody Immunotherapy

44. Supplementary Data from Preclinical Evaluation of a Novel SHIP1 Phosphatase Activator for Inhibition of PI3K Signaling in Malignant B Cells

45. Supplementary Table 7 from Genetics and Prognostication in Splenic Marginal Zone Lymphoma: Revelations from Deep Sequencing

46. CCR Translation for this Article from Expression of Mutated IGHV3-23 Genes in Chronic Lymphocytic Leukemia Identifies a Disease Subset with Peculiar Clinical and Biological Features

47. Supplemetary data from STING Activation Reverses Lymphoma-Mediated Resistance to Antibody Immunotherapy

48. Supplementary Data from Expression of Mutated IGHV3-23 Genes in Chronic Lymphocytic Leukemia Identifies a Disease Subset with Peculiar Clinical and Biological Features

Catalog

Books, media, physical & digital resources